StreetInsider.com News Articles

Form 6-K Evotec SE For: Oct 15

Thu, 15 Oct 2026 08:43:00 -0400

si-local-file:///var/storage/secattach/20261015/27190410.html

Evotec names Dr. Joanna Holbrook as chief scientific officer

Thu, 15 Oct 2026 05:57:59 -0400

Evotec SE (NASDAQ: EVO) has appointed Dr. Joanna Holbrook as Chief Scientific Officer and member of its Management Board, effective November 1, 2026, according to a company statement.

Dr. Holbrook most recently served as Therapy Area Head for Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk. Before that, she was Chief Scientific Officer at UK biotech Biomodal and Vice President of Translational Medicine at BenevolentAI. She also held academic positions as Professor of Bioinformatics at the University of Southampton and Senior Principal Investigator at the Singapore Institute for Clinical Sciences (A*STAR), with an adjunct

Evotec names Dr. Joanna Holbrook as chief scientific officer

Thu, 15 Oct 2026 05:57:59 -0400

Evotec SE (NASDAQ: EVO) has appointed Dr. Joanna Holbrook as Chief Scientific Officer and member of its Management Board, effective November 1, 2026, according to a company statement.

Evotec names Dr. Joanna Holbrook as chief scientific officer

Thu, 15 Oct 2026 05:57:59 -0400

Evotec SE (NASDAQ: EVO) has appointed Dr. Joanna Holbrook as Chief Scientific Officer and member of its Management Board, effective November 1, 2026, according to a company statement.

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Thu, 15 Oct 2026 02:04:00 -0400

Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation
Brings more than 25 years of global experience in pharma, biotechnology and academia

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Thu, 15 Oct 2026 02:04:00 -0400

Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation
Brings more than 25 years of global experience in pharma, biotechnology and academia

Form SCHEDULE 13D/A Evotec SE Filed by: Mubadala Investment Co PJSC

Wed, 14 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27187770.html

Form 6-K Evotec SE For: Oct 14

Wed, 14 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261014/27183216.html

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR3 at TD Cowen

Tue, 13 Oct 2026 09:35:53 -0400

TD Cowen analyst Brendan Smith lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR3.00 (from EUR4.00) while maintaining a rating.

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR3 at TD Cowen

Tue, 13 Oct 2026 09:35:53 -0400

TD Cowen analyst Brendan Smith lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR3.00 (from EUR4.00) while maintaining a rating.

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR3 at TD Cowen

Tue, 13 Oct 2026 09:35:53 -0400

TD Cowen analyst Brendan Smith lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR3.00 (from EUR4.00) while maintaining a rating.

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR3 at TD Cowen

Tue, 13 Oct 2026 09:35:53 -0400

TD Cowen analyst Brendan Smith lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR3.00 (from EUR4.00) while maintaining a rating.

Form 6-K Evotec SE For: Sep 29

Tue, 29 Sep 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260929/27116846.html

Evotec CSO Cord Dohrmann to step down after 16 years

Tue, 29 Sep 2026 06:02:59 -0400

Evotec SE (NASDAQ: EVO) announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, following a mutual agreement between Dohrmann and the company.

Dohrmann has served as CSO and member of the Management Board since 2010. The company said a search for his successor is ongoing.

Chief Executive Officer Dr. Christian Wojczewski credited Dohrmann with contributing to the company's scientific infrastructure over his 16-year tenure, including the development of iPSC-based technologies and omics capabilities.

"I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years," Wojczewski said. "The robust

Evotec CSO Cord Dohrmann to step down after 16 years

Tue, 29 Sep 2026 06:02:59 -0400

Evotec SE (NASDAQ: EVO) announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, following a mutual agreement between Dohrmann and the company.

Dohrmann has served as CSO and member of the Management Board since 2010. The company said a search for his successor is ongoing.

"I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years," Wojczewski said. "The robust

Evotec CSO Cord Dohrmann to step down after 16 years

Tue, 29 Sep 2026 06:02:59 -0400

Evotec SE (NASDAQ: EVO) announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, following a mutual agreement between Dohrmann and the company.

Dohrmann has served as CSO and member of the Management Board since 2010. The company said a search for his successor is ongoing.

"I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years," Wojczewski said. "The robust

Evotec Announces Chief Scientific Officer Transition

Tue, 29 Sep 2026 02:04:00 -0400

Dr. Cord Dohrmann to step down as of September 30, 2026
Search ongoing for a successor

Evotec Announces Chief Scientific Officer Transition

Tue, 29 Sep 2026 02:04:00 -0400

Dr. Cord Dohrmann to step down as of September 30, 2026
Search ongoing for a successor

Form 6-K Evotec SE For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915802.html

Form 6-K Evotec SE For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915802.html

Form 6-K Evotec SE For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915802.html

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.

Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Thu, 06 Aug 2026 02:16:00 -0400

Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs
Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need

HAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.

Under the agreement,